Biogen Idec

By: Gao & Shaleah

What is Biogen Idec?

One of the world's oldest independent biotech companies. An American global biotechnology, based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.

Founded in 1978.

Biogen manufactures, markets/or distributes more than 10 drugs in the U.S.

They treat cancer, neurological diseases, and autoimmune diseases. The company's most important products are Avonex & Rituxan, which treat multiple sclerosis (MS) & non-Hodgkin's lymphomas.


At Biogen, they are committed to improving the lives of patients living with serious illnesses and pursuing new treatments.


Biogen produces treatment for hemophilia & has grown by more than 50% over the last 3 years.

Machelle Sanders, has led the companay ever since 2011, who is now promoted to VP of the company.

Biogen focused on areas where they can have the greatest impact & benefit for patients worldwide.

Haemophilia A

-A rare chronic genetic disorder, in which the ability of a person's blood to clot is impaired due to missing or reduced levels of a protein,


An international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients.

Clinical Trials

Daclizumab High-yield process (Relapsing-remitting multiple sclerosis) - Filed

Aducanumab (Alzheimer's disease)- Phase 3

BG00011 (Idiopathic pulmonary fibrosis)- Phase 2

Anti-alpha-synuclein mAb (Parkinson's Disease)- Phase 1